New publication in Lancet Neurology: A clinical trial investigating NG101, a targeted antibody therapy for spinal cord injury, shows encouraging preliminary results for patients with incomplete injuries. The potential benefits observed in specific patient groups highlight exciting avenues for future research.
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial. More…